Content Detail

• Content META

  Title	Q3 2024 Airsculpt Technologies Inc Earnings Call
  ID	4028649
  External ID	063434174
  Author
  Published Date	Nov. 9, 2024, 12:34 a.m.
  Summary	Q3 2024 Airsculpt Technologies Inc Earnings Call Thomson Reuters StreetEvents Sat, Nov 9, 2024, 1:34 AM 20 min read In This Article: AIRS +20.72% Presentation Operator Greetings and welcome to Airscul
  Tags	None
  URL	No URL
  Sentiment	Negative: 0.01047    Neutral: 0.79182    Positive: 0.19771
  Relevance	0.03600

• Content Details

  Content ID	2306129
  Key	bbaaced0-959e-4656-b22f-3173f73c72f8
  Content	Q3 2024 Airsculpt Technologies Inc Earnings Call Thomson Reuters StreetEvents Sat, Nov 9, 2024, 1:34 AM 20 min read In This Article: AIRS +20.72% Presentation Operator Greetings and welcome to Airsculpt Technologies in third quarter, 2024 earnings conference call. (Operator Instructions)It is now my pleasure to introduce your host, MS Allison Malkin from ICR. Thank you, Miss Malkin. You may begin. Good morning everyone and thank you for joining us to discuss our Airsculpt Technologies results for the third quarter of fiscal 2024. Joining me on the call today is interim Chief Executive Officer and Chief Financial Officer Dennis Dean. Before we begin, I would like to remind you that this conference call may include forward-looking statements. These statements may include our future expectations regarding financial results and guidance, market opportunities and our growth risk and uncertainties that may impact these statements and could cause actual future results to differ materially from currently projected results are described in this morning's press release and the reports we will file with the SEC, all of which can be found on our website at investors dot airscape dotcom. We undertake no obligation to revise or update any forward-looking statements or information except as required by law during our call today. We will also reference certain non-GAAP financial measures. We use no GAAP measures in some of our financial discussions as we believe they more accurately represent the true operational performance and underlying results of our business. A reconciliation of these measures can be found in our earnings release as filed this morning and in our most recent 10-Q, which will also be available on our website for today's call. Dennis will begin with an overview of the quarter and share an update on our strategic initiatives followed by a review of our financials and guidance. Following our prepared remarks, we will open the call to take the questions you have for us today. With that, I'll turn the call over to Dennis. Good morning, everyone and thank you for joining today's call. Our third quarter results were in line with our expectations and included solid progress on our back to basics priorities. These priorities focus on three initiatives, improving the conversion of current and prior lead volumes to perform cases, ensuring our recent DE NOVO center openings are successful and bettering cost management. We believe this approach has us on the right track to improve performance as we navigate a continuing dynamic macro environment briefly highlighting our financials revenue totaled $42.5 million in the third quarter, down 9.1% year over year with case volume down 4.3% from the prior year. Third quarter, same store cases declined 8.1% over the prior year but improved significantly from the decline of 14% report in the second quarter of this year adjusted EBITDA was $4.7 million or 11% of revenue versus $9.1 million or 19.4% of revenue in the prior year quarter, the decline in revenue accounted for $3 million of the decrease. With the remainder mostly due to the costs related to new De Novo openings. As a reminder, it takes approximately 3 to 4 months for new centers to reach profitability. And let me now turn to the progress made in our back to basics priorities as it relates to converting demand for air sculp to cases in our lowest seasonal quarter of the year. And while our core customers are still facing macro challenges, we are starting to see measured improvement in converting leads to consultations. We believe this is tribal to our return to a more targeted advertising approach of page search advertising at the center level and our continued engagement with historical leads. As you're aware, air scult is a considered purchase with an average spend between 12 and $13,000 in this environment. It is common to see a longer time frame just convert leads into cases. Historically, our experience shows that it takes approximately 45 days to convert a lead to a case for the third quarter. It was closer to 60 days. In response, we have implemented a number of initiatives to drive leads and conversions to cases. And let me share some examples. We are now utilizing salesforce software to help us reconnect with customer leads in our database and better nurture and communicate with them to offer a more catered experience which should help increase conversion to cases over time. Importantly, as these established leads, convert to cases, they do so at no additional cost which will in turn help lower our customer acquisition cost. We have also added new payment options that give consumers more flexibility to finance procedures. We believe this is an effective way to drive incremental revenue by allowing eligible consumers to schedule higher price procedures which should also help us improve our margins. Our second priority is to drive productivity from our recent de Novo locations. We continue to be pleased with the performance of our 2023 De Novo center class. Each of the US centers that have been open for 12 months are performing ahead of our stated year one revenue objective of $4.5 million. Similarly, these centers are also achieving a payback of less than one year. We believe the excellent performance of these centers is the result of our more seasoned recruiting sales and operation teams which should also benefit our recent new center openings as well as it relates to new locations. It was a busy quarter. We opened centers in Kansas City, Kansas, Columbus, Ohio, Deerfield, Illinois, and Birmingham, Michigan. And while early so far, we are pleased with our new cohort performance. Our fifth and final opening for 2024 is expected to open in White Plains, New York in the next few weeks. As of September 30th 2024 we operated 31 facilities versus 27 at the end of the third quarter of 2023. Looking ahead, we have a strong pipeline of new centers overall, we continue to believe we have significant opportunity to operate over 100 centers in the medium term and have three locations currently identified for 2025 and expect to increase that number in the next few months. Turning to our third priority. The quarter also saw continued progress on our cost savings goal as we have identified and achieved half of our planned $1 million savings goal for the back half of the year and on an annualized basis, we expect to deliver savings of $2 million and we will continue to prudently invest savings into higher return marketing activities as we work to increase leads and case growth. Let me now share additional insights into our financial performance and guidance. As mentioned revenue for the quarter was$ 42.5 million a 9.1% decline versus the prior year quarter with same store revenue down 13%. The decline in revenue. This quarter was mainly driven by lower case and lead volume due to the challenging consumer spending environment. In addition, while our average revenue per case, this quarter was $12,984. And on the high side of our 12 to $13,000 range, it compares to $13,658 in last year's third quarter, which was unusually high driven by patients having more areas treated than any other quarter. Notably, while leads are lower, our ability to convert leads to consultations showed some improvement which we attribute to our return to a more efficient marketing spend. The percentage of patients using financing to pay for procedures was 53% which is consistent with recent quarters. As a reminder, we receive full payment of all procedures upfront and we have no recourse related to patients who finance their procedures with third party vendors cost of service as a percentage of revenue was 41.8% versus 38.8% over the prior year period. Our recent de novo openings reflected 130 basis point impact while the remaining percentage increase was due to our inability to flex certain fixed costs such as rent and nursing, selling it in general. And administrative expenses increased $466,000 in the quarter compared to the same period in fiscal year 2023. As mentioned, we worked to contain our corporate G&A cost this quarter and was able to achieve a reduction of a half a million dollars in the quarter. However, this was offset by year over year increase in our marketing spin. Our customer acquisition cost for the quarter was $2900 per case. As compared to $2750 in the prior year. On a sequential basis, we decreased our advertising spend by $4.1 million as a result of discontinuing certain brand awareness spending initiatives. Notably, our efforts to reduce CAC are working as reflected in the sequential decrease in our C A of $425 versus the second quarter of 2024. As our marketing and sales efforts begin to convert to cases, we expect to see further reduction in our customer acquisition costs going forward and continue to move toward our goal of approximately $2000 adjusted EBITDA was $4.7 million compared to $9.1 million for the fiscal 2023 3rd quarter adjusted EBITA margin was 11% compared to 19.4% in the prior year quarter. And adjusted loss for the quarter was 1.4 million or a loss of 2¢ per diluted share. Turning to our balance sheet as of September 30th 2024 cash was $6 million and we had $5 million available on our revolving credit facility. Our gross debt outstanding is $71.3 million and our leverage ratio is 2.2 times cash flow from operations for the quarter was$ 1.8 million compared to$ 0.6 million in the prior year quarter. And we invested $ 4.9 million this quarter in De Novo facilities. Let me now turn to our outlook for the remainder of the year. As noted in our preliminary sales release issued on October 24th. We have increased the midpoint of our revenue guidance for 2024 to a range of $183 million to $189 million. As compared to the guidance issued with second quarter results in August for revenue in the range of $180 million to $190 million. We are also maintaining our full year guidance for a JBI in the range of $23 million to $28 million. Before I wrap up my remarks, I would like to share an update within our organization. I am pleased to announce the promotion of Philip body to Chief Accounting Officer for the past 3.5 years. Philip has served as senior Vice President and corporate controller at Esco where he has been a highly valuable and trusted partner of mine. Prior to joining Esco, Philip held senior finance roles with significant experiences in the health care industry. I am looking forward to continuing to benefit from his business acumen as we work to improve our financial foundation. Additionally, the search for a permanent co is well underway. We have conducted several interviews and are narrowing our list of candidates in hopes of announcing a new leader of air sculpt in the coming weeks. And finally, despite the challenged consumer spending backdrop, we believe our back to basics approach to the business is working and will enable us to continue to improve our revenue and profitability trend. In summary, we remain excited about our business prospects as we see significant opportunity to capitalize on the $11 billion total addressable market in which we operate with proven results and a proven track record of opening and operating centers and a cash generative model that will allow us to navigate this dynamic period and continue to invest to support our future growth. With that. I'd like to turn the call over to the operator for some questions, operator. Story Continues Question and Answer Session Operator Thank you. (Operator instructions) Joshua Raskin , Nephron Research LLC. Please go ahead. Hi, thanks and good morning. I guess the first one just starting on the new centers. I know you have four in the quarter. It looks like the case count on those four was about 130 cases in the quarter. I know Deerfield in Birmingham we were right at the end of the quarter, but I think you said that was sort of in line. How should we think about that ramp? And you know, what sort of contributions in the fourth quarter are you expecting? Hey, Josh, thanks for the question this morning. So as we said, it was very much in line as you pointed out, Deerfield and Birmingham really did not, you know, contribute, hardly anything in the, in the, in the quarter for us. Kansas City opened up first full month I believe was August and, Columbus was the first full month of September. So as you, as you pointed out, it was, it didn't get a full complement of those activities, you know, those centers are, you know, we're improving. Well, I mean, I think what you would look at is is, you know, probably looking at, you know, obviously you can expect a little over doubling that, that amount. You know, as we pointed out the, the centers that we opened up last year, continue to perform. Well, when we think about, you know, how a center performs on a full year basis, you know, our sort of expectation is a range of around $4.5 million of revenue for the full year. And, you know, while we don't give out each center individual information, you know, those centers last year performed above that, our current centers that are open are performing very much in line. And so we, we expected, you know, you know, it's not a full quarter of that, obviously from the standpoint of the 4.5 million, but we do expect some pretty significant improvement over what we saw in the third quarter. Alright, that's, that's helpful, maybe switching topics. Just I'm curious of your views on the impact of G LP ones involved. If you add more data on how many patients are using them prior to a procedure or seeing you. And I don't know if you're seeing any specific changes in demand for skin tightening procedures, things like that. Yes, still no significant change from what we've talked about in previous quarters around it. We, we have seen some, some publications recently that, that are, you know, strongly suggesting that that the G LP one are leading to people considering, you know, body contouring procedures, you know, specifically as it relates to skin tightening, I think that's an area that we need to be leaning into a little bit further and I expect us to do that in the you know in the coming in the coming year, skin tightening as, you know, I mean, if you've been around anyone that's been on the GOP one, that's an area that you can tell that that is a needed aspect of it. You know, it just again, the GOP ones have been sort of a catalyst of drawing people to, you know, what, what, what can I do with my you know, my appearance. And so obviously, the the the weight loss aspect has been working for a lot of people and we think skin tightening is definitely an area that we focus on. But currently we do skin tightening. Obviously, we talked about ACO itself, you know, performing really good skin tightening just with the modality itself. We do add on to, to various ACO procedures with a product from a renuvion product to, to assist enhancing skin tightening as well. But I think there's, there's further work we can do around that. We've been kicking around several ideas internally and, you know, it's a process we want to be diligent about and make sure that when we do, you know, roll out new products, new items, new services that we do those clinically well. And obviously, we want to make sure that they give the results that, that, you know, people have grown to expect from Airsculpt. Makes sense Maybe just one last one. I think that you mentioned new payment options to finance for consumers. What, what does that mean? Does that mean more financing? I assume it means more financing available? Are you? I assume you guys aren't taking on the financing risk, but I'm just curious what that meant. Yeah, so that, that's correct. We still aren't taking on financing risk from that standpoint. It's just not an area that we want to to do right now. What it is Josh is, is we're, we're looking at opportunities for customers that qualify to, to and, and, and obviously we want to do it based on, on procedures that are probably a little larger in nature from a, from a revenue standpoint. We're looking at like extending payment options beyond some of our traditional payment options and many of our patients qualify for a, some of it like a 12 month, same as cash program. And we're working with vendors or financing vendors to kind of open up opportunities again for the right qualified candidates to extend that to say 24 months, 18 to 24 months again based on their quality from the standpoint of credit. And so that, that gives that patient the opportunity to be able to pay for that over a two year period versus a 12 month period, which we think will, you know, enhance our our revenue per case and also possibly bring in some, you know, additional volume particularly as it relates to the, you know, challenges the consumer facing currently. Perfect. Thanks a lot. Operator (Operator Instructions) Korinne Wolfmeyer , Piper Sandler Companies. Please go ahead. Hey, good morning. Thanks for taking the question. I'd like to touch a little bit on the, the cost of service this quarter. It was as a percent of sales. It did step up a little bit. Could you provide a little bit of color on what the driver here was? Was it just a function of lower volumes or anything else going on? And then how to think about the proper run rate of that as we head into Q4 and then even the early parts of 2025. Thanks. Hey, thanks, Ken. And yeah, as you pointed out, the cost of service did tick up in the quarter, which is typical for us in the third quarter is I remind you guys, the third quarter is our most challenging quarter of the year from a, from a revenue standpoint, even when there, there's not a consumer, you know, macro challenge out there. So we always tend to see a little bit of an uptick in the third quarter as relates to just the, the decline in, in the revenue from that standpoint. One of the major drivers, Korea was opening up four new centers in the quarter. Not only do we have pre opening related costs in there, but we also have is, as you, as you guys probably recall, it takes us 3 to 4 months for a center to ramp up to being cash flow profitable. And so, you know, many of those you know, while we're pleased with the, the current state of how volume is starting to pick up there, we're still incurring, you know, somewhat of a full brunt of the costs at the center level there. And so that's really causing a pretty big clip of that percentage increase about about 100 and 30 basis points was, was related to just the de novo activity. So expect that part to be able to, you know, begin to come down as those centers begin to ramp up further in the, in the fourth quarter. So highly expect improvement as we move into the fourth quarter to something very similar to to where we were earlier in the year. Second quarter obviously is a very, you know, healthy quarter for us from a revenue because it's our highest. But, but again, I think going back to that, you know, where we have historically been, is where we ought to land. And again, as those De Novos ramp up, we'll see some, some significant improvement there. Great, that's helpful. And then moving through the P&L the S DNA step down a good amount and I know there's some cost savings going on, but it sounds like you're still prioritizing marketing and you know, customer spend. So any color on the, the building blocks around G&A and then how we should be thinking about that heading into Q4. Thanks. Yeah, sequentially we took out about four, a little over $4 million in marketing spend again compared to the second quarter. That's, that is our number one area of focus trying to, to reach the right optimal level of marketing spend. I mean, our, our main focus currently is is heavily in the search, the search aspect of it. Search is much more expensive on a lead basis on a cost per lead standpoint. Doing search marketing, search activities are is definitely more expensive to us, but it also provides a much quicker turnaround. And because those patients have a lot more intent, they're very intent in buying the products and looking for body sculpting. And so, we're just trying to strike the right balance there between, you know, making sure that we're getting the right return on what we're spending there. But, you know, we may see a little bit of an uptick in the fourth quarter in our marketing expense. But nowhere, you know, close to where we were in the, in the second quarter. But again, it's striking the right balance is, is something that we're very focused on. We did do some things around corporate overhead that gave us about a half a million dollar benefit in the, in the current quarter. We expect that to continue on. Most of those were staffing related and, and sort of identifying what we call sort of middle management type positions that, you know, we felt like we're, we could do in the near term with without from that standpoint. And so we were able to achieve that cost and expect again that to continue on in the fourth quarter and, and also going into next year. So continuing to do a lot of work around cost, making sure that we're identifying cost that we, we need in the business and areas that we can can potentially do some additional reductions on as long as we don't, you know, sacrifice, you know, quality and, and, and safety and those sorts of things. Great. Thanks so much. Operator Thank you, ladies and gentlemen, we have reached the end of question and answer session. I would now like to turn the floor over to Dennis for closing comments. I thank you again for joining us today and we look forward to speaking with you when we report fourth quarter results and we're going to see many of you. I believe in the upcoming days and weeks related to some investor events. Thank you very much. Operator Thank you. This concludes today's teleconference. You may disconnect your lines at this time. Thank you for your participation. View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories
  Content Reference URL	None

• Publisher

  None

• Data Source

  Data Source Name	Yahoo Finance News
  Data Source Type	news
  Data Source URL	https://finance.yahoo.com/
  Description	Yahoo! Finance is a media property that is part of the Yahoo! network. It provides financial news, data and commentary including stock quotes, press releases, financial reports, and original content. It also offers some online tools for personal finance management.
  Weight	10